Smith & Nephew refused knee revision coverage from insurers
This article was originally published in Clinica
Smith & Nephew (S&N) has engaged itself in a tussle with two of its product liability insurers after the latter refused to cover the cost of replacement surgery related to S&N's macrotextured cement-free knee implants. While the company is uncertain of the duration and outcome of this dispute, it is nevertheless bracing itself for an £80m ($153m) hit to its year-end profits.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.